The triple combination (mSDC2 + CEA + CA72-4) achieved a sensitivity of 96.9% (63/65) and a specificity of 78.3% (47/60) in the CRC, and a sensitivity of 50% (19/38) for advanced adenomas. The gene discussed is CEACAM5; the disease is adenoma.